0001725160-21-000185.txt : 20210820
0001725160-21-000185.hdr.sgml : 20210820
20210820125942
ACCESSION NUMBER: 0001725160-21-000185
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210818
FILED AS OF DATE: 20210820
DATE AS OF CHANGE: 20210820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Epperly Melissa B,
CENTRAL INDEX KEY: 0001807359
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 211192785
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, INC.
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_162947877030994.xml
FORM 4
X0306
4
2021-08-18
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001807359
Epperly Melissa B,
C/O ZENTALIS PHARMACEUTICALS, INC.
530 SEVENTH AVENUE, SUITE 2201
NEW YORK
NY
10018
0
1
0
0
Chief Financial Officer
Common Stock
2021-08-18
4
P
0
1326
51.997
A
258400
D
Common Stock
2021-08-19
4
P
0
8285
51.9976
A
266685
D
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $51.96 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $51.93 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
By: /s/ Melissa B. Epperly
2021-08-18